Sinopharm Group Ltd Stock Retained Earnings
| SHTDY Stock | USD 13.31 0.33 2.54% |
SINOPHARM GROUP LTD fundamentals help investors to digest information that contributes to SINOPHARM GROUP's financial success or failures. It also enables traders to predict the movement of SINOPHARM Pink Sheet. The fundamental analysis module provides a way to measure SINOPHARM GROUP's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SINOPHARM GROUP pink sheet.
SINOPHARM |
SINOPHARM GROUP LTD Company Retained Earnings Analysis
SINOPHARM GROUP's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current SINOPHARM GROUP Retained Earnings | 11.43 B |
Most of SINOPHARM GROUP's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SINOPHARM GROUP LTD is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, SINOPHARM GROUP LTD has a Retained Earnings of 11.43 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Distribution industry. The retained earnings for all United States stocks is 22.5% lower than that of the firm.
SINOPHARM Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SINOPHARM GROUP's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of SINOPHARM GROUP could also be used in its relative valuation, which is a method of valuing SINOPHARM GROUP by comparing valuation metrics of similar companies.SINOPHARM GROUP is currently under evaluation in retained earnings category among its peers.
SINOPHARM Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 16.78 B | |||
| Shares Outstanding | 624.13 M | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 6.27 X | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 521.05 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 20.76 B | |||
| Net Income | 7.76 B | |||
| Cash And Equivalents | 38.21 B | |||
| Cash Per Share | 61.23 X | |||
| Total Debt | 8.42 B | |||
| Debt To Equity | 0.71 % | |||
| Current Ratio | 1.31 X | |||
| Book Value Per Share | 105.05 X | |||
| Cash Flow From Operations | 9.31 B | |||
| Earnings Per Share | 1.86 X | |||
| Price To Earnings To Growth | 50.92 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.72 | |||
| Market Capitalization | 8.61 B | |||
| Total Asset | 335.41 B | |||
| Retained Earnings | 11.43 B | |||
| Working Capital | 32.26 B | |||
| Current Asset | 130.51 B | |||
| Current Liabilities | 98.25 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.15 % | |||
| Net Asset | 335.41 B | |||
| Last Dividend Paid | 0.75 |
About SINOPHARM GROUP Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SINOPHARM GROUP LTD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SINOPHARM GROUP using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SINOPHARM GROUP LTD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SINOPHARM Pink Sheet Analysis
When running SINOPHARM GROUP's price analysis, check to measure SINOPHARM GROUP's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SINOPHARM GROUP is operating at the current time. Most of SINOPHARM GROUP's value examination focuses on studying past and present price action to predict the probability of SINOPHARM GROUP's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SINOPHARM GROUP's price. Additionally, you may evaluate how the addition of SINOPHARM GROUP to your portfolios can decrease your overall portfolio volatility.